Insider Buying: Second Sight Medical Products Inc (EYES) Director Buys 11,709 Shares of Stock

Second Sight Medical Products Inc (NASDAQ:EYES) Director Gregg Williams acquired 11,709 shares of the company’s stock in a transaction that occurred on Thursday, October 11th. The shares were acquired at an average cost of $1.60 per share, for a total transaction of $18,734.40. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Gregg Williams also recently made the following trade(s):

  • On Tuesday, October 9th, Gregg Williams acquired 10,458 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.64 per share, for a total transaction of $17,151.12.
  • On Friday, October 5th, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $27,305.00.
  • On Wednesday, October 3rd, Gregg Williams acquired 24,075 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.79 per share, for a total transaction of $43,094.25.
  • On Friday, September 28th, Gregg Williams acquired 9,223 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.90 per share, for a total transaction of $17,523.70.
  • On Monday, October 1st, Gregg Williams acquired 25,098 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.88 per share, for a total transaction of $47,184.24.
  • On Wednesday, September 26th, Gregg Williams acquired 10,878 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.96 per share, for a total transaction of $21,320.88.
  • On Monday, September 24th, Gregg Williams acquired 15,520 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.86 per share, for a total transaction of $28,867.20.
  • On Friday, September 21st, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.80 per share, for a total transaction of $28,575.00.
  • On Wednesday, September 19th, Gregg Williams acquired 29,616 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.82 per share, for a total transaction of $53,901.12.
  • On Monday, September 17th, Gregg Williams acquired 15,875 shares of Second Sight Medical Products stock. The shares were acquired at an average cost of $1.79 per share, for a total transaction of $28,416.25.

Second Sight Medical Products stock traded up $0.03 during trading hours on Friday, hitting $1.63. The stock had a trading volume of 146,210 shares, compared to its average volume of 391,197. The firm has a market capitalization of $127.44 million, a price-to-earnings ratio of -2.76 and a beta of 3.07. Second Sight Medical Products Inc has a 1-year low of $1.05 and a 1-year high of $2.58.

Second Sight Medical Products (NASDAQ:EYES) last posted its earnings results on Tuesday, August 7th. The medical device company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The company had revenue of $1.91 million for the quarter, compared to analyst estimates of $2.21 million. Second Sight Medical Products had a negative return on equity of 432.45% and a negative net margin of 418.82%. On average, equities research analysts anticipate that Second Sight Medical Products Inc will post -0.58 earnings per share for the current fiscal year.

A number of brokerages recently weighed in on EYES. Zacks Investment Research raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Monday, September 24th. HC Wainwright set a $5.00 price objective on Second Sight Medical Products and gave the stock a “buy” rating in a report on Wednesday, August 8th.

About Second Sight Medical Products

Second Sight Medical Products, Inc, together with its subsidiaries, develops, manufactures, and markets prosthetic devices to restore functional vision of blind individuals in the United States, Canada, Europe, the Middle East, and Asia. It offers Argus II System, which treats outer retinal degenerations, such as retinitis pigmentosa.

Recommended Story: What is the Dividend Aristocrat Index?

Insider Buying and Selling by Quarter for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply